Patents by Inventor Kenneth Joseph Valenzano

Kenneth Joseph Valenzano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ?-galactosidase A and 1-deoxygalactonojirimycin co-formulation
    Patent number: 9694056
    Abstract: The present application provides for compositions comprising ?-galactosidase A in combination with an active site-specific chaperone for the ?-galactosidase A, and methods for treating Fabry disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an ?-galactosidase A enzyme formulation.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: July 4, 2017
    Assignee: AMICUS THERAPEUTICS, INC.
    Inventors: Richie Khanna, Kenneth Joseph Valenzano, Susan Elizabeth Fowles
  • High concentration alpha-glucosidase compositions for the treatment of Pompe disease
    Patent number: 9404100
    Abstract: The present application provides for compositions comprising high concentrations of acid ?-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: August 2, 2016
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Kenneth Joseph Valenzano, John Crowley, Richie Khanna, John Flanagan
  • ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN CO-FORMULATION
    Publication number: 20150174214
    Abstract: The present application provides for compositions comprising ?-galactosidase A in combination with an active site-specific chaperone for the ?-galactosidase A, and methods for treating Fabry disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an ?-galactosidase A enzyme formulation.
    Type: Application
    Filed: July 16, 2013
    Publication date: June 25, 2015
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Richie Khanna, Kenneth Joseph Valenzano, Susan Elizabeth Fowles
  • DOSING REGIMENS FOR THE TREATMENT OF POMPE DISEASE
    Publication number: 20150086530
    Abstract: The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxynojirimycin and enzyme replacement therapy for the treatment of Pompe disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of 1-deoxynojirimycin hydrochloride and alglucosidase alfa for the treatment of Pompe disease.
    Type: Application
    Filed: May 2, 2013
    Publication date: March 26, 2015
    Inventors: Douglas Stuart Greene, Kenneth Joseph Valenzano
  • High Concentration Alpha-Glucosidase Compositions for the Treatment of Pompe Disease
    Publication number: 20150044194
    Abstract: The present application provides for compositions comprising high concentrations of acid ?-glucosidase in combination with an active site-specific chaperone for the acid ?-glucosidase, and methods for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject such compositions. The present application also provides methods for increasing the in vitro and in vivo stability of an acid ?-glucosidase enzyme formulation.
    Type: Application
    Filed: March 7, 2013
    Publication date: February 12, 2015
    Inventors: Kenneth Joseph Valenzano, John Crowley, Richie Khanna, John Flanagan
  • DOSING REGIMENS FOR THE TREATMENT OF FABRY DISEASE
    Publication number: 20140219986
    Abstract: The presently disclosed subject matter provides a dosing regimen and administration schedule for the use of 1-deoxygalactonojirimycin and enzyme replacement therapy for the treatment of Fabry disease. The presently disclosed subject matter further provides a dosing regimen and administration schedule for the use of migalastat hydrochloride and agalsidase for the treatment of Fabry disease.
    Type: Application
    Filed: March 8, 2012
    Publication date: August 7, 2014
    Applicant: AMICUS THERAPEUTICS ,INC.
    Inventors: Douglas Stuart Greene, Kenneth Joseph Valenzano